Paxman

62.2

SEK

-3.72 %

Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

-3.72%

-10.63%

-5.18%

-3.72%

+19.62%

+79.77%

+13.92%

+69.02%

+470.64%

Paxman is active in scalp cooling, which is used for patients being treated for chemotherapy. The company's product Paxman Scalp Cooler is used to minimize the patient's hair loss during treatment. The Scalp Cooler is a stand-alone, mobile, and electrically powered cooling unit that cools the patient's scalp via a cooling cap. The company was founded in 1996 and has its headquarter in Karlshamn.

Market cap

1.18B SEK

Turnover

7.6M SEK

Revenue

253.01M

EBIT %

13.24 %

P/E

29.48

Dividend yield-%

-

Financial calendar

16.5

2025

General meeting '25

16.5

2025

Interim report Q1'25

20.8

2025

Interim report Q2'25

ShowingAll content types

Press release2/24/2025, 8:18 AM

Redeye: Paxman Q4’2024 - Outlook is still excellent and CIPN becoming the real deal

Press release2/21/2025, 11:48 AM

See Redeye's interview with CEO Richard Paxman

Regulatory press release2/21/2025, 7:00 AM

Paxman’s Record-Breaking Streak Continues!

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release12/16/2024, 2:15 PM

Paxman Announces Passage of New York Law Requiring Insurance Coverage of Scalp Cooling Devices to Help Prevent Hair Loss During Cancer Treatment

Press release12/5/2024, 8:04 PM

PAXMAN's major shareholders are reducing their shareholdings

Press release11/18/2024, 9:22 AM

Redeye: Paxman - Potential for a stellar 2026

Press release11/15/2024, 1:10 PM

See Redeye's interview with CEO Richard Paxman

Regulatory press release11/15/2024, 7:00 AM

Strong Performance Continues

Press release11/4/2024, 2:22 PM

PAXMAN Announces that US Centers for Medicare and Medicaid Services (CMS) continues to support scalp cooling and increases rate for 2025 beyond the initial proposed rate

Press release10/18/2024, 3:45 PM

Paxman Announces New CPT® Category I Codes from the American Medical Association for Mechanical Scalp Cooling

Press release9/27/2024, 12:10 PM

Analyst Group interviews CEO Richard Paxman

Press release8/28/2024, 11:50 AM

Paxman receives an initial order under contract for the provision of scalp cooling systems to the U.S. Department of Veterans Affairs (VA) for the National Precision Oncology Program (NPOP)

Press release8/22/2024, 6:18 AM

Redeye: Paxman Q2’24 - The strongest report to date

Regulatory press release8/21/2024, 7:00 AM

PAXMAN publishes its interim report for Q2 2024

Press release7/3/2024, 2:40 PM

Paxman secures contract for the provision of scalp cooling systems to the U.S. Department of Veterans Affairs (VA) for the National Precision Oncology Program (NPOP)

Press release6/29/2024, 10:45 AM

MASCC/AFSOS/ISOO 2024 Annual Meeting Features Presentation of Important Preliminary Data in Cryotherapy Side-Effect Management for Safety & Efficacy of Paxman Limb Cryocompression Device

Press release5/24/2024, 5:13 AM

Redeye: Paxman - Strength in numbers

Regulatory press release5/23/2024, 10:40 AM

Press release from PAXMAN AB’s 2024 Annual General Meeting

Regulatory press release5/23/2024, 7:00 AM

PAXMAN publishes its interim report for Q1 2024

Press release4/26/2024, 6:00 AM

Paxman publishes the company’s annual report for 2023

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.